Research Analysts’ Weekly Ratings Updates for Verastem (VSTM)

Verastem (NASDAQ: VSTM) recently received a number of ratings updates from brokerages and research firms:

• 9/11/2026 – Verastem had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 9/11/2026 – Verastem had its “buy” rating reaffirmed by BTIG Research. They now have a $18.00 price target on the stock.
• 9/5/2026 – Verastem was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/4/2026 – Verastem was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/15/2026 – Verastem was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/10/2026 – Verastem was given a new $13.00 price target by Mizuho. They now have an “outperform” rating on the stock.
• 8/7/2026 – Verastem was given a new $12.00 price target by Guggenheim. They now have a “buy” rating on the stock.
• 7/25/2026 – Verastem was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling

In related news, CEO Dan Paterson sold 20,871 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $4.18, for a total transaction of $87,240.78. Following the completion of the transaction, the chief executive officer owned 591,242 shares in the company, valued at approximately $2,471,391.56. This represents a 3.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,262 shares of company stock worth $111,897 in the last ninety days. Corporate insiders own 1.94% of the company’s stock.

Verastem Oncology is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s principal products include avutometinib, a RAF/MEK pathway inhibitor, and defactinib, a focal adhesion kinase (FAK) inhibitor. The company has studied these therapies both individually and in combination, with the goal of improving cancer-cell response and overcoming treatment resistance.